This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genzyme’s Multiple Sclerosis Franchise Featured At ECTRIMS

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio ® (teriflunomide) and Lemtrada™ (alemtuzumab) clinical development programs will be presented during the 29 th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18 th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5.

The recent European Commission approvals of Aubagio and Lemtrada make this year’s ECTRIMS particularly significant for Genzyme’s MS Franchise,” said Genzyme CEO and President David Meeker. “ As we prepare to launch both products, we look forward to presenting these new data, which highlight the unique potential of our products to treat a broad spectrum of relapsing remitting MS patients and reflect our strong commitment to the MS community.”

Presentations at ECTRIMS/RIMS featuring Aubagio and Lemtrada are as follows.

Aubagio:

Oral Platform Presentation
  • TOPIC Main Outcomes: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with Clinically Isolated Syndrome (Parallel Session 3 – 99; October 3; 12:00 p.m. CEST)

Poster Presentations
  • Immune Response to Neoantigen and Recall Antigens in Healthy Subjects Receiving Teriflunomide (Poster Session I – P622; October 3; 3:45 p.m. CEST)
  • Teriflunomide: No Effects on Sperm DNA (Poster Session II – P1187; October 4; 3:30 p.m. CEST)
  • Long-Term Safety and Efficacy of Teriflunomide in Patients with Relapsing Forms of Multiple Sclerosis in the TEMSO Extension Trial (Poster Session I – P544; October 3; 3:45 p.m. CEST)
  • Pooled Efficacy Data From Two Phase 3 Placebo-Controlled Trials of Oral, Once-Daily Teriflunomide (Poster Session I – P618; October 3; 3:45 p.m. CEST)
  • Updated Pregnancy Outcomes from the Teriflunomide Clinical Development Programme: Retrospective Analysis of the Teriflunomide Clinical Trial Database (Poster Session I – P541; October 3; 3:45 p.m. CEST)
  • Pooled Safety Data from Three Placebo-Controlled Teriflunomide Studies (Poster Session I – P633; October 3; 3:45 p.m. CEST)
  • Teriflunomide Reduces Relapse-Related Sequelae, Severe Relapses, Hospitalisations and Corticosteroid Use: Pooled Data from the Phase 3 TEMSO and TOWER Studies (Poster Session II – P1095; October 4; 3:30 p.m. CEST)
  • Impact of Severe Relapses on Disability, Fatigue, and Health-Related Quality of Life Outcomes: A Pooled Dataset of the Phase 3 TEMSO and TOWER Studies (Poster Session II – P1093; October 4; 3:30 p.m. CEST)

Lemtrada:

Poster Presentations
  • Alemtuzumab Improves EDSS via Effects on Functional Systems: CARE-MS II (Poster Session I – P649; October 3; 3:45 p.m. CEST)
  • Reduction of Disability with Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in CARE-MS II: Three-Year Follow-Up (Poster Session I – P592; October 3; 3:45 p.m. CEST)
  • Infection Risk with Alemtuzumab in Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Results from the CARE-MS I and CARE-MS II Trials (Poster Session I – P603; October 3; 3:45 p.m. CEST)
  • Lymphocyte Subset Dynamics Following Alemtuzumab Treatment in the CARE-MS II study (Poster Session I – P531; October 3; 3:45 p.m. CEST)
  • Adverse Event Profile of Alemtuzumab in Active Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three-Year Follow-Up (Poster Session II – P1053; October 4; 3:30 p.m. CEST)
  • Lymphocyte Counts and Efficacy Outcomes After Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients: The CARE-MS Studies (Poster Session I – P515; October 3; 3:45 p.m. CEST)
  • Preservation of Lymphocyte Migratory Ability Following Anti-CD52 Therapy (Poster Session II – P1207; October 4; 3:30 p.m. CEST)
  • Detection, Incidence, and Management of Glomerulonephritis in the Alemtuzumab Clinical Development Program (Poster Session I – P597; October 3: 3:45 p.m. CEST)
  • Immunogenicity of Alemtuzumab Does Not Impact Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis Patients in the CARE-MS I Study (Poster Session I – P523; October 3; 3:45 p.m. CEST)

Abstracts are available on the ECTRIMS/RIMS website.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs